Privately held Viacyte Inc., of San Diego, has closed on about $27 million in private funding, the remainder of its $80 million series D stock financing from late 2018.
Within a month of disclosing a CA$175.6 million (US$124.7 million) award from the Canadian government to use its antibody discovery platform for the analysis of patients who have recovered from COVID-19, Abcellera Biologics Inc. closed a $105 million series B financing aimed at expanding its capacity and investing in new technologies that complement its antibody discovery engine.
LONDON – Exscientia Ltd. has closed a $60 million series C funding, attracting Novo Holdings as new investor to lead the round, which will enable the artificial intelligence (AI) specialist to progress its first in-house program to the clinic before the end of 2020.
HONG KONG – South Korean conglomerate SK Group is preparing to list its subsidiary, SK Biopharmaceuticals Co. Ltd., on the Stock Market Division of the Korea Exchange.
DUBLIN – Monte Rosa Therapeutics Inc. emerged from stealth mode with $32.5 million in funding commitments from series A investors Versant Ventures and New Enterprise Associates to enable it to bring new science into the increasingly crowded field of targeted protein degradation.
LONDON – Human challenge specialist Open Orphan plc has raised £12 million (US$14.6 million) in a placing to accelerate development of COVID-19 challenge study models, to meet demand from vaccines and therapeutics developers worldwide.
BEIJING – Androgen receptor (AR)-related disease specialist Kintor Pharmaceutical Ltd., of Suzhou, China, raised $240 million on the Hong Kong Stock Exchange (HKEX) on May 22 by issuing 92.3 million shares at HK$20.15 apiece. The IPO was oversubscribed by 551 times, showing the city’s biotech fever.
RSS
